ImmunoVec secures a **$40.7 million grant** to develop its **polymeric nanoparticle platform**, targeting a first-in-human trial for autoimmune disease treatments. The technology focuses on **reprogramming immune cells in vivo** to modulate disease pathways. This funding supports preclinical advancements toward clinical validation.
ImmunoVec secures up to **$40.7 million** from **ARPA-H’s EMBODY program** to advance **in vivo cell engineering** targeting autoimmune diseases. The funding supports the company’s stealth-mode research in modifying immune cells directly inside the body. ImmunoVec aims to develop precision therapies by leveraging ARPA-H’s focus on breakthrough biomedical technologies.
ImmunoVec emerges from stealth mode with a **$40.7 million award** from ARPA-H’s EMBODY program to advance its **in vivo cell engineering platform** for treating autoimmune diseases. The funding supports development of its first-in-class therapy, transitioning from pre-clinical studies toward clinical validation. ARPA-H Program Manager Daria Fedyukina, Ph.D., leads the initiative.
